| Title |
Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis
|
|---|---|
| Published in |
BMC Pulmonary Medicine, February 2016
|
| DOI | 10.1186/s12890-016-0187-3 |
| Pubmed ID | |
| Authors |
Jingtao Gao, Yan Ma, Jian Du, Guofeng Zhu, Shouyong Tan, Yanyong Fu, Liping Ma, Lianying Zhang, Feiying Liu, Daiyu Hu, Yanling Zhang, Xiangqun Li, Liang Li, Qi Li |
| Abstract |
The failure of current Standard Short-Course Chemotherapy (SCC) in new and previously treated cases with tuberculosis (TB) was mainly due to drug resistance development. But little is known on the characteristics of acquired drug resistant TB during SCC and its correlation with SCC failure. The objective of the study is to explore the traits of acquired drug resistant TB emergence and evaluate their impacts on treatment outcomes. A prospective observational study was performed on newly admitted smear positive pulmonary TB (PTB) cases without drug resistance pretreatment treated with SCC under China's National TB Control Program (NTP) condition from 2008 to 2010. Enrolled cases were followed up through sputum smear, culture and drug susceptibility testing (DST) at the end of 1, 2, and 5 months after treatment initiation. The effect factors of early or late emergence of acquired drug resistant TB , such as acquired drug resistance patterns, the number of acquired resistant drugs and previous treatment history were investigated by multivariate logistic regression; and the impact of acquired drug resistant TB emergence on treatment failure were further evaluated. Among 1671 enrolled new and previously treated cases with SCC, 62 (3.7 %) acquired different patterns of drug resistant TB at early period within 2 months or later around 3-5 months of treatment. Previously treated cases were more likely to develop acquired multi-drug resistant TB (MDR-TB) (OR, 3.8; 95 %CI, 1.4-10.4; P = 0.015). Additionally, acquired MDR-TB cases were more likely to emerge at later period around 3-5 months after treatment starting than that of non-MDR-TB mainly appeared within 2 months (OR, 8.3; 95 %CI, 1.7-39.9; P = 0.008). Treatment failure was associated with late acquired drug resistant TB emergence (OR, 25.7; 95 %CI, 4.3-153.4; P < 0.001) with the reference of early acquired drug resistant TB emergence. This study demonstrates that later development of acquired drug resistant TB during SCC is liable to suffer treatment failure and acquired MDR-TB pattern may be one of the possible causes. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Venezuela, Bolivarian Republic of | 3 | 60% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Scientists | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 97 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 19% |
| Researcher | 17 | 18% |
| Student > Ph. D. Student | 11 | 11% |
| Student > Bachelor | 8 | 8% |
| Student > Doctoral Student | 5 | 5% |
| Other | 14 | 14% |
| Unknown | 24 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 36 | 37% |
| Nursing and Health Professions | 6 | 6% |
| Immunology and Microbiology | 5 | 5% |
| Agricultural and Biological Sciences | 5 | 5% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Other | 11 | 11% |
| Unknown | 30 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2016.
All research outputs
#6,949,716
of 22,856,968 outputs
Outputs from BMC Pulmonary Medicine
#517
of 1,921 outputs
Outputs of similar age
#114,606
of 397,031 outputs
Outputs of similar age from BMC Pulmonary Medicine
#7
of 38 outputs
Altmetric has tracked 22,856,968 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 1,921 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 397,031 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.